SAN DIEGO—In the pre-ACR Convergence 2023 Review Course, Rebecca Sadun, MD, PhD, assistant professor in medicine and pediatrics, Duke University School of Medicine, Durham, N.C., focused on transitions from pediatric to adult rheumatology care for patients with juvenile idiopathic arthritis (JIA).
A study from Glerup et al. demonstrated that many patients with juvenile idiopathic arthritis achieved drug-free remission over 18 years of follow-up and that remission rates remained stable between years 8 and 18 of the study period.
In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
Machine learning is a tool that may help pediatric rheumatologists distinguish between different subtypes of juvenile idiopathic arthritis (JIA) and predict treatment response.
NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…
Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.
ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…
Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.
NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say. The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second…